Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Pfs'
Pfs published presentations and documents on DocSlides.
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
Pay for Success: Innovative Financing to Improve Child Outcomes
by dominic513
Jennifer Tschantz; Early Childhood Research to Pra...
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
by felicity
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
by willow
Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...
YIR On Demand Lung Benjamin Levy, MD
by jovita
Assistant Professor. Johns Hopkins School of Medic...
Summary 2011 Founded 2010
by eliza
in Houston. Vision: To be the leader in the develo...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
by TravelingSoulmate
PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
2022 Spring Oncology Conference
by byrne
Evolving Treatment Strategies. for CLL/SLL and MCL...
Presentation
by wang
pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...
Nouveautés dans le CBNPC métastatique
by vizettan
Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...
Game Plan Trends in ovarian cancer
by alexa-scheidler
Diagnostic work-up. Treatment. The most commonly ...
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Interpretation of the Great Plains Polygonal Fault
by luanne-stotts
Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Applying “Pay for Success” Social Impact Finance to Ear
by luanne-stotts
Janis Dubno, Voices for Utah Children. Andrea Phi...
Thierry Le Chevalier, MD
by aaron
How . d. o . International Regulatory Groups View...
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Ray Jones
by danika-pritchard
Director of Solutions Architecture and Field Enab...
Partnerships for Success
by test
Creating Positive School Experiences And Develop...
Beyond Secret Handshakes:
by pasty-toler
Affiliation-Hiding Authenticated Key Exchange. Fr...
2014 Oklahoma Business Summit
by marina-yarberry
Sarah Roberts, Inasmuch Foundation, Program Offic...
Thierry Le Chevalier, MD
by yoshiko-marsland
How . d. o International Regulatory Groups View C...
Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial
by ayaan
Progression-Free Survival of Isa-. KRd. in High-R...
Symptomatic control of functioning pancreatic NET
by titan
Dr.. . Wouter. T. Zandee, MD, PhD. University Me...
Physician Schedule Proposed Freestanding Radiation Oncology Centers
by dennis955
Association of Freestanding Radiation Oncology Cen...
INTRODUCTION RESULTS
by arjun383
Mason Alford, MSc. a. , . Candace J. Grisham, MS. ...
Please note: The views expressed within this presentation are the personal opinion of the author.
by callen
NTRK. and SARCOMA CONNECT groups.. This content i...
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
by zen
knowledge. ). Incorporate evidence-based research ...
Mauricio Lema Medina – Clínica de Oncología Astorga / Clínica SOMA, Medellín
by delcy
Trastuzumab-emtansine. : A . very. . nice. . poi...
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
by hadley
Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...
Module 9: HER2-Positive and Triple-Negative BC
by unita
Percent with Patients. Number of Patients (Median)...
Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in
by fanny
. A subsidiary analysis of the UK NCRI RAPID study...
Load More...